WALTHAM, Mass., February 25, 2025--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) ("Thermo Fisher"), the world leader in serving science, today announced that the company has entered ...

Thermo Fisher Scientific is growing its lab equipment empire with a deal to buy 3M’s former purification and filtration business for $4.1 billion. Waltham-based Thermo is buying the business ...

Update 9:45am: Companies confirm deal details. Thermo Fisher Scientific (NYSE:TMO) confirmed that it agreed to purchase Solventum's purification and fitration unit for $4.1 billion in cash.

On the heels of a move to reduce its viral vector manufacturing workforce, Thermo Fisher is beefing up its biologics production business through a $4.1 billion acquisition. The buyout target is ...

(Reuters) -Contract drug manufacturer Thermo Fisher Scientific said on Tuesday it will buy Solventum's purification and filtration business for about $4.1 billion, sending the latter's shares up ...

The business, which provides filters for the purification of food or beverages and drugs during development, brought in about $1 billion in revenue in 2024, Thermo said. Evercore analyst Vijay ...

Highly Complementary to Thermo Fisher’s Bioproduction Business and Strengthens Offering in the High Growth Bioprocessing Market Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher ...

Thermo Fisher said it is paying about $4.1 billion in cash for the business. The Journal reported in October that Solventum, the healthcare company spun off from 3M last year, had retained bankers ...

Thermo Fisher (TMO) is close to a deal for Solventum’s (SOLV) purification and filtration business, The Wall Street Journal’s Lauren Thomas reports. A transaction, which could be announced as ...

Thermo Fisher (TMO) announced that the company has entered into a definitive agreement with Solventum (SOLV) to acquire Solventum’s Purification & Filtration business for approximately $4.1B in ...

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe ...

but one of the conclusions of the pilot was that a pre-requisite for adoption will be "robust systems in place ensuring that the patient can easily access the package leaflet for their medicine in ...